サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1563910

牛呼吸器疾患治療の世界市場

Bovine Respiratory Disease Treatment

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
牛呼吸器疾患治療の世界市場
出版日: 2024年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

牛呼吸器疾患治療の世界市場は2030年までに34億米ドルに達する見込み

2023年に22億米ドルと推定される牛呼吸器疾患治療の世界市場は、分析期間2023-2030年にCAGR 6.4%で成長し、2030年には34億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるワクチンは、CAGR 7.8%を記録し、分析期間終了時には14億米ドルに達すると予測されます。抗生物質分野の成長率は、分析期間中CAGR 6.5％と推定されます。

米国市場は5億7,810万米ドルと推定、中国はCAGR9.7％で成長すると予測

米国の牛呼吸器疾患治療市場は、2023年に5億7,810万米ドルと推定されます。世界第2位の経済大国である中国は、2023-2030年のCAGRを9.7%として、2030年までに8億810万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1%と5.8%と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界の牛呼吸器疾患治療市場- 主要動向と促進要因まとめ

牛呼吸器疾患とは何か？

牛呼吸器疾患（Bovine Respiratory Disease：BRD）は、世界中の牛、特に肉牛と乳牛に影響を及ぼす重大な健康問題です。最近輸送された牛によく発症するため、「輸送熱」と呼ばれることが多いが、その影響ははるかに広く、あらゆる年齢と種類の牛に影響を及ぼします。この病気は複雑で多因子性の病態であり、輸送、混血、環境の変化など様々なストレス要因と、ウイルス、細菌、マイコプラズマなどの感染因子の相互作用によって起こる。BRDは、増体重の減少、飼料要求率の上昇、死亡率の増加、治療や予防対策にかかる費用により、深刻な経済的損失を引き起こすことで有名です。また、動物福祉にも多大な影響を及ぼすため、より効果的で人道的な治療法を求める声が高まっています。BRDは複雑かつ多面的であるため、その治療は獣医学および家畜管理における重要な焦点となっています。

牛呼吸器疾患の現在の治療戦略はどのように進化しているのか？

ここ数年、牛呼吸器疾患の治療には大きな進展が見られました。この疾患の病理学的な理解が深まり、新しい治療法が開発されたからです。従来の治療戦略では、発熱や痛みを抑える抗炎症薬などの支持療法に加え、病気の細菌成分を標的とした広域抗生物質の使用が一般的でした。しかし、抗生物質耐性やこのような治療法の有効性に対する懸念から、より標的を絞ったアプローチが模索されるようになった。新しい治療法は、診断ツールを用いてBRDの特定の症例に関与する特定の病原体を特定し、よりオーダーメイドの治療プロトコルを可能にする精密医療にますます焦点が当てられています。さらに、動物の免疫反応を高めて感染をより効果的に撃退することを目的とした免疫調節療法への関心も高まっています。これらの進歩は、回復率を向上させるだけでなく、抗生物質の過剰使用に伴うリスクを軽減する、より持続可能で効果的な治療レジメンへのシフトを意味します。

牛呼吸器疾患の予防における新たな動向とは？

牛呼吸器疾患の予防は重要な分野となっており、業界では、発症後に治療するよりも予防する方が費用対効果が高く、有益であると認識されています。ワクチン接種プログラムはBRD予防の基礎であり、最も一般的なウイルスおよび細菌性病原体を標的とするワクチンが利用可能です。より効果的なワクチンの開発は、鼻腔内スプレーのような新しい投与方法を含め、業界で進行中の動向です。もうひとつの重要な動向は、データ分析、センサー、モニタリング・システムを活用して、リスクのある家畜を早期に特定し、病気が蔓延する前に予防措置を講じる精密畜産技術の利用です。これらの技術により、牛群の継続的なモニタリングが可能になり、BRDの発生を大幅に減らすことができる早期介入が可能になります。さらに、輸送中のストレスの軽減、栄養の最適化、適切な飼育環境の確保など、牛群管理全般の改善が重視されるようになってきており、これらすべてが疾病発生のリスク低下に寄与しています。

牛呼吸器疾患治療市場の成長の促進要因は？

牛呼吸器疾患治療市場の成長は、技術の進歩、最終用途の変化、消費者行動の進化に直接関連するいくつかの要因によって牽引されています。主な促進要因の1つは、動物医療における精密医療の採用が増加していることで、より正確で効果的な治療が可能になり、回復率の向上や死亡率の減少につながっています。畜牛の頭数の増加に伴い、効果的なBRD治療オプションへの需要が高まっているため、特に新興国市場における畜産の拡大も市場の成長を後押ししています。さらに、人道的で持続可能な条件下で生産された肉や乳製品に対する消費者の需要が高まっており、畜産業者はBRDのような疾病に対してより効果的で倫理的な治療プロトコルを採用するよう求められています。また、家畜への抗生物質使用削減を求める規制上の圧力も、免疫調節療法や標的抗菌薬療法などの代替治療法の開発と採用を加速させています。最後に、診断技術の進歩により、獣医師がBRDを迅速かつ正確に診断することが容易になり、よりタイムリーで効果的な治療につながるため、市場の拡大がさらに加速しています。

調査対象企業の例（注目の12社）

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco
  • Merck & Co., Inc.
  • Vetoquinol S.A.
  • Virbac Group
  • Zoetis Services LLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10783

Global Bovine Respiratory Disease Treatment Market to Reach US$3.4 Billion by 2030

The global market for Bovine Respiratory Disease Treatment estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Antibiotics segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$578.1 Million While China is Forecast to Grow at 9.7% CAGR

The Bovine Respiratory Disease Treatment market in the U.S. is estimated at US$578.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$808.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Bovine Respiratory Disease Treatment Market - Key Trends and Drivers Summarized

What Is Bovine Respiratory Disease and Why Is It a Major Concern?

Bovine Respiratory Disease (BRD) is a significant health issue affecting cattle populations worldwide, particularly in beef and dairy herds. It is often referred to as "shipping fever" because it commonly occurs in cattle that have been recently transported, but its impact is far broader, affecting all ages and types of cattle. The disease is a complex, multifactorial condition that results from the interaction of various stress factors—such as transportation, co-mingling, and environmental changes—with infectious agents including viruses, bacteria, and mycoplasma. BRD is notorious for causing severe economic losses due to decreased weight gain, higher feed conversion rates, increased mortality, and the cost of treatment and preventive measures. It also has a substantial impact on animal welfare, leading to a push for more effective and humane treatment options. The complexity and multifaceted nature of BRD make its treatment a critical focus area in veterinary medicine and livestock management.

How Are Current Treatment Strategies Evolving for Bovine Respiratory Disease?

In recent years, there have been significant advancements in the treatment of Bovine Respiratory Disease, driven by a better understanding of the disease's pathology and the development of new therapeutic interventions. Traditional treatment strategies have typically involved the use of broad-spectrum antibiotics to target the bacterial component of the disease, alongside supportive care such as anti-inflammatory drugs to reduce fever and pain. However, concerns about antibiotic resistance and the efficacy of such treatments have led to the exploration of more targeted approaches. Newer therapies are increasingly focused on precision medicine, which involves the use of diagnostic tools to identify the specific pathogens involved in a particular case of BRD, allowing for more tailored treatment protocols. Additionally, there has been a growing interest in immunomodulatory therapies that aim to boost the animal’s immune response to fight off the infection more effectively. These advancements represent a shift towards more sustainable and effective treatment regimens that not only improve recovery rates but also help mitigate the risks associated with antibiotic overuse.

What Are the Emerging Trends in Bovine Respiratory Disease Prevention?

The prevention of Bovine Respiratory Disease has become a key area of focus, as the industry recognizes that preventing the disease is more cost-effective and beneficial than treating it after it occurs. Vaccination programs are a cornerstone of BRD prevention, with vaccines available that target the most common viral and bacterial pathogens. The development of more effective vaccines, including those that can be administered through novel delivery methods such as intranasal sprays, is an ongoing trend in the industry. Another significant trend is the use of precision livestock farming techniques, which leverage data analytics, sensors, and monitoring systems to identify at-risk animals early and take preventive measures before the disease can spread. These technologies allow for the continuous monitoring of cattle herds, enabling early intervention that can significantly reduce the incidence of BRD. Additionally, there is a growing emphasis on improving overall herd management practices, such as reducing stress during transportation, optimizing nutrition, and ensuring proper housing conditions, all of which contribute to a lower risk of disease outbreaks.

What Is Driving the Growth of the Bovine Respiratory Disease Treatment Market?

The growth in the Bovine Respiratory Disease treatment market is driven by several factors directly related to technological advancements, changing end-use practices, and evolving consumer behavior. One of the key drivers is the increasing adoption of precision medicine in veterinary care, which allows for more accurate and effective treatments, leading to higher recovery rates and reduced mortality. The expansion of livestock farming, particularly in developing regions, is also fueling market growth, as the demand for effective BRD treatment options rises in tandem with the growth of the cattle population. Moreover, there is a growing consumer demand for meat and dairy products produced under humane and sustainable conditions, which has pushed livestock producers to adopt more effective and ethical treatment protocols for diseases like BRD. Regulatory pressures to reduce antibiotic use in livestock have also accelerated the development and adoption of alternative treatment methods, such as immunomodulatory therapies and targeted antimicrobial therapies. Finally, advancements in diagnostic technologies are making it easier for veterinarians to quickly and accurately diagnose BRD, leading to more timely and effective treatments, further driving the market's expansion.

Select Competitors (Total 12 Featured) -

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco
  • Merck & Co., Inc.
  • Vetoquinol S.A.
  • Virbac Group
  • Zoetis Services LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bovine Respiratory Disease Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Respiratory Infections Propels Demand for Advanced Treatment Solutions
    • Increasing Focus on Animal Welfare Expands Addressable Market Opportunity for Humane Treatment Options
    • Growing Awareness of Antimicrobial Resistance Strengthens the Business Case for Non-Antibiotic Therapies
    • Innovations in Vaccination Technology Spur Growth in Preventive Care Solutions
    • Regulatory Pressures on Antibiotic Use Throw the Spotlight on Alternative Therapies
    • Here's How Precision Livestock Farming Drives Adoption of Targeted Treatment Approaches
    • Expanding Global Livestock Population Accelerates Demand for Bovine Respiratory Disease Treatments
    • Increasing Integration of Digital Health Tools in Veterinary Care Generates New Market Opportunities
    • Growing Consumer Demand for Quality Meat and Dairy Products Drives Adoption of Effective Disease Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bovine Respiratory Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • INDIA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030
  • AFRICA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Bovine Respiratory Disease Treatment by Segment - Vaccines, Antibiotics, NSAIDs and Other Segments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Bovine Respiratory Disease Treatment by Segment - Percentage Breakdown of Value Sales for Vaccines, Antibiotics, NSAIDs and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION